These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36828647)

  • 1. A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Macedo Silva V; Lima Capela T; Freitas M; Boal Carvalho P; Magalhães J; Cotter J
    Helicobacter; 2023 Jun; 28(3):e12962. PubMed ID: 36828647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
    Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
    Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
    PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
    Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
    Tungtrongchitr N; Bongkotvirawan P; Ratana-Amornpin S; Siramolpiwat S; Eiamsitrakoon T; Gamnarai P; Wongcha-Um A; Yamaoka Y; Pawa KK; Vilaichone RK
    Sci Rep; 2024 Apr; 14(1):8986. PubMed ID: 38637591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
    Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
    Pih GY; Choi KD; Gong EJ; Na HK; Ahn JY; Lee JH; Jung KW; Kim DH; Song HJ; Lee GH; Jung HY
    Helicobacter; 2021 Feb; 26(1):e12759. PubMed ID: 33113240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
    Yozgat A; Kasapoğlu B; Demirci S; Coşkun Sökmen F
    Rev Esp Enferm Dig; 2021 Jul; 113(7):490-493. PubMed ID: 33233910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
    Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
    Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.